Aurigene & Curis To Present Data From IRAK-4 Inhibitor Program - Quick Facts

(RTTNews) - Aurigene announced the company and its partner Curis Inc. (CRIS) will be presenting data from two programs at the American Associate of Cancer Research Annual Meeting. Aurigene will present data for its Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, which is currently in preclinical development. Aurigene and Curis will present data from their interleukin-1 receptor association kinase-4, or IRAK-4, inhibitor program.

Aurigene is a specialized, discovery stage biotechnology company, developing therapies to treat cancer and inflammatory diseases. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered multiple clinical compounds through these partnerships. Curis is engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecule antagonists of PD-L1 and IRAK4 and file IND application for both molecules in 2015.